Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, April 05, 2017
Heptares Therapeutics , a wholly owned subsidiary of Sosei Group Corporation, has achieved an important milestone in its immuno-oncology collaboration with AstraZeneca, which is focused on the development of AZD4635 (HTL-1071) as a potential new ...
read more
Heptares Therapeutics, a wholly owned subsidiary of Sosei Group Corporation announced that it has entered into a drug discovery and licensing agreement with Daiichi Sankyo Company, Limited focused on a single G protein-coupled receptor (GPCR) ...
read more
Heptares has been notified by Teva a preclinical candidate calcitonin gene-related peptide antagonist has been nominated for advancement as an investigational treatment for migraine.
read more
Heptares Therapeutics announced its plans to relocate to a new facility at Granta Park, Cambridge, UK.
read more
Heptares Therapeutics announced the launch of a new research collaboration under its ORBIT initiative with New York University School of Medicine.
read more
Shanghai Henlius Biotech announced the company's drug substance line and drug product line for trastuzumab biosimilar have passed the EU GMP on-site inspection.
read more
Hemispherx Biopharma has reached an agreement with Avrio Biopharmaceuticals, Irvine California, to serve as an additional contract manufacturer of Hemispherx’s experimental drug, Ampligen®, also known by its generic name rintatolimod.
read more
Wednesday, October 19, 2016
Hemispherx Biopharma has completed its technology transfer of the Ampligen® manufacturing processes to Avrio Biopharmaceuticals. The transfer consists of providing Avrio with all information that is relevant to the manufacturing process of Ampligen® ...
read more
Tuesday, February 06, 2018
HemaCare and Charles River Laboratories have formed a partnership to advance human immune system research by developing a more efficient and reliable method of working with humanized mice.
read more
HemaCare has signed a long term lease to relocate its operations and corporate headquarters to a larger nearby site in the San Fernando Valley.
read more
Wednesday, November 20, 2019
HemaCare has expanded its portfolio of GMP-compliant cellular material with the launch of GMPrime bone marrow aspirate.
read more
HemaCare has expanded its portfolio of disease state materials in response to increased demand from therapeutic and diagnostic developers.
read more
HemaCare has expanded its portfolio of GMP-compliant cellular material with the launch of the GMPrime cryopreserved leukopak.
read more
Helsinn and MEI Pharma announced findings from a genetic mutation analysis of patients in a Phase II clinical study of the investigational drug pracinostat and azacitidine in AML.
read more
Wednesday, August 02, 2017
Helsinn and MEI Pharma announced the first patient has been dosed in the Phase 3 study of pracinostat in combination with azacitidine in adults with newly diagnosed AML who are unfit to receive intensive induction chemotherapy.
read more